CFFTICystic Fibrosis Foundation Therapeutics, Inc. (est. 2000)
References in periodicals archive ?
These statements include, but are not limited to, those relating to future development plans and the timing of any additional clinical studies for ALTU-238 and Altus' other development candidates, the expected effect of such studies in establishing the value of ALTU-238 or any other development candidate, the amount of time that the Company's existing cash resources will be available to fund operating expenses, the anticipated effects and expected costs of the strategic realignment, including the workforce reductions, discussions between CFFTI and Altus and the future of the Trizytek program.